The ASPRE trial (2017) established that combined first-trimester screening followed by low-dose aspirin reduces early-onset preeclampsia by approximately what percentage in high-risk women?
- A 62% ✓
- B 25%
- C 38%
- D 75%
Explanation
The ASPRE randomised controlled trial by Rolnik et al. (NEJM 2017) demonstrated that low-dose aspirin (150 mg nightly, started before 16 weeks) in women identified as high-risk by first-trimester combined screening (maternal factors, uterine artery Doppler, MAP, PlGF, PAPP-A) reduced early preterm preeclampsia (<34 weeks) by 62% compared to placebo. The risk reduction for preterm preeclampsia (<37 weeks) was approximately 62%, while the overall reduction for term preeclampsia was smaller (~23%). This trial established the combined algorithm screening model now adopted by NICE and FIGO guidelines.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.